Sandoz Ltd has issued a class two recall for certain batches of Co-amoxiclav 125 mg/31.25mg/5ml and 250 mg/62.5mg/5ml powder for oral suspension.
The Medicines and Healthcare products Regulatory Agency (MHRA) said the company issued its recall as a precaution after detecting a potential packaging problem related to poor seal adherence which could cause clumping of the powder within the bottle.
“A poor bottle seal could lead to degradation of the clavulanic acid within the powder and could potentially render the product ineffective,” the MHRA statement read.
Pharmacy teams are asked to quarantine all the remaining stocks of the impacted batches and return it to the original supplier.
|Batch Number||Expiry Date||Pack Size||First Distributed|
|HT6202||Feb 2021||100ml||Sep 2018|
|HT7923||Feb 2021||100ml||Jul 2018|